Change of International Restless Legs Syndrome Study Group Rating Scale subscales with treatment and placebo: a pilot study

Background: In 2003, the 10-question International Restless Legs Syndrome Study Group Rating Scale (IRLS) was developed as a means of assessing the severity of restless legs syndrome. Two subscales were identified: symptom severity (SS 1) and symptom impact (SS 2). Only one study has investigated th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Parkinsonism & Restless Legs Syndrome 2014-01, Vol.4, p.27
Main Authors: Mitchell, Ulrike, Hilton, Sterling
Format: Article
Language:English
Subjects:
Dopamine
Legs
Placebo effect
Restless legs syndrome
Sleep
Studies
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: In 2003, the 10-question International Restless Legs Syndrome Study Group Rating Scale (IRLS) was developed as a means of assessing the severity of restless legs syndrome. Two subscales were identified: symptom severity (SS 1) and symptom impact (SS 2). Only one study has investigated the subscales' responsiveness to a 12-week treatment with ropinirole. This current study was undertaken to assess the impact of a 4-week, non-pharmaceutical treatment on the two subscales and to explore whether or not both subscales were impacted by the observed placebo effect. Methods: The pooled data from questionnaires of 58 patients (41 from both treatment groups and 17 from the sham treatment control group), who participated in two clinical studies, were reviewed. Their change in score over a 4-week trial was computed. The average change in both subscales in both groups was computed and t-tests were performed. Results: In the treatment group, the average scores of both subscales changed significantly from baseline to week 4 (P
ISSN:1927-7733
1927-7733
2624-3733
DOI:10.2147/JPRLS.S53015